Boston Scientific Corp [BSX] stock is trading at $96.43, up 0.86%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BSX shares have gain 4.60% over the last week, with a monthly amount drifted -0.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Boston Scientific Corp [NYSE: BSX] stock has seen the most recent analyst activity on October 03, 2025, when Erste Group downgraded its rating to a Hold. Previously, Oppenheimer upgraded its rating to Outperform on September 08, 2025, and kept the price target unchanged to $125. On June 16, 2025, Leerink Partners initiated with a Outperform rating and assigned a price target of $118 on the stock. Needham upgraded its rating to a Buy but stick to its price target of $113 on April 16, 2025. Deutsche Bank upgraded its rating to a Buy but $108 remained the price target by the analyst firm on January 10, 2025. Needham downgraded its rating to Hold for this stock on October 18, 2024. In a note dated May 30, 2024, Goldman initiated an Buy rating and provided a target price of $90 on this stock.
Boston Scientific Corp [BSX] stock has fluctuated between $85.98 and $109.50 over the past year. Currently, Wall Street analysts expect the stock to reach $127.08 within the next 12 months. Boston Scientific Corp [NYSE: BSX] shares were valued at $96.43 at the most recent close of the market. An investor can expect a potential return of 31.78% based on the average BSX price forecast.
Analyzing the BSX fundamentals
Boston Scientific Corp [NYSE:BSX] reported sales of 19.35B for the trailing twelve months, which represents a growth of 20.34%. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.13 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 95.56 points at the first support level, and at 94.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 96.93, and for the 2nd resistance point, it is at 97.44.
Ratios To Look Out For
For context, Boston Scientific Corp’s Current Ratio is 1.51. Also, the Quick Ratio is 0.96, while the Cash Ratio stands at 0.1. Considering the valuation of this stock, the price to sales ratio is 7.39, the price to book ratio is 6.11 and price to earnings (TTM) ratio is 51.58.
Transactions by insiders
Recent insider trading involved Butcher Arthur C, EVP& Grp Pres, MedSurg & APAC, that happened on Dec 01 ’25 when 17313.0 shares were sold. Officer, ARTHUR C BUTCHER completed a deal on Dec 01 ’25 to buy 17313.0 shares. Meanwhile, Director Zane Ellen M sold 12891.0 shares on Nov 06 ’25.
